GNPX GENPREX INC Business Restructuring 8-K Filing 2025 - License Agreement Update Genprex Inc. entered into a new exclusive license agreement with the University of Pittsburgh for gene therapy technology related to diabetes, replacing previous agreements, and will pay up to approximately $4.825 million in various fees and royalties.Get access to all SEC 8-K filings of the GENPREX INC